Addition of incretin therapy to metformin in type 2 diabetes

被引：31

作者：

Scheen, Andre J. ^{[1
]}

Radermecker, Regis P.

机构：

[1] Univ Liege, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium

来源：

LANCET | 2010年 / 375卷 / 9724期

关键词：

DIPEPTIDYL PEPTIDASE-4 INHIBITOR; NON-INFERIORITY; OPEN-LABEL; EFFICACY; SAFETY; SITAGLIPTIN; EXENATIDE; LIRAGLUTIDE; GLIMEPIRIDE; MELLITUS;

D O I：

10.1016/S0140-6736(10)60399-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1410 / 1412

页数：3

共 13 条

[1]

BERGENSTAL R, 2009, 69 SCI SESS AM DIAB

[2] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[3] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].

Charbonnel, Bernard ;

Karasik, Avraham ;

Liu, Ji ;

Wu, Mei ;

Meininger, Gary .

DIABETES CARE, 2006, 29 (12) :2638-2643

[4] Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].

DeFronzo, RA ;

Ratner, RE ;

Han, J ;

Kim, DD ;

Fineman, MS ;

Baron, AD .

DIABETES CARE, 2005, 28 (05) :1092-1100

[5]

DeFronzo RA, 2008, CURR MED RES OPIN, V24, P2943, DOI [10.1185/03007990802418851, 10.1185/03007990802418851 ]

[6] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[8] Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy [J].

Ferrannini, E. ;

Fonseca, V. ;

Zinman, B. ;

Matthews, D. ;

Ahren, B. ;

Byiers, S. ;

Shao, Q. ;

Dejager, S. .

DIABETES OBESITY & METABOLISM, 2009, 11 (02) :157-166

[9] Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, D. M. ;

Buse, J. B. ;

Davidson, M. B. ;

Ferrannini, E. ;

Holman, R. R. ;

Sherwin, R. ;

Zinman, B. .

DIABETOLOGIA, 2009, 52 (01) :17-30

[10] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial [J].

Nauck, M. A. ;

Meininger, G. ;

Sheng, D. ;

Terranella, L. ;

Stein, P. P. .

DIABETES OBESITY & METABOLISM, 2007, 9 (02) :194-205

← 1 2 →